Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Acrocephalosyndactylia 4Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Urinary Bladder Neoplasms 1Solid Tumor 1Recurrence 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Myeloproliferative Disorders 1Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel 1Eosinophilia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

senaparib 7pembrolizumab 7Irinotecan 6Paclitaxel 5Docetaxel 5Cisplatin 5Capecitabine 5Nivolumab 4Fluorouracil 4Bevacizumab 4Rifampin 3Midazolam 3Leucovorin 3Itraconazole 3Injections 3pertuzumab 2ontuxizumab 2navoximod 2atezolizumab 2Gemcitabine 2vofatamab 1tremelimumab 1trastuzumab duocarmazine 1talazoparib 1sotorasib 1sintilimab 1saracatinib 1rucaparib 1ridaforolimus 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Solid Tumor × pemigatinib × Clear all
NCT04258527 2021-07-23

Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
12 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡